Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography

ObjectiveTo investigate the difference in the risk of hematobilia after therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in patients with different primary diseases. MethodsA retrospective analysis was performed for the clinical data of 685 patients with pancreaticobiliary diseases...

Full description

Bibliographic Details
Main Authors: WANG Qunru, ZHANG Yong, MOU Dong
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Hepatology 2017-05-01
Series:Linchuang Gandanbing Zazhi
Online Access:http://www.lcgdbzz.org/qk_content.asp?id=8199
id doaj-78eb0fd9999e44a9844d07c096c61044
record_format Article
spelling doaj-78eb0fd9999e44a9844d07c096c610442020-11-24T21:53:40ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562017-05-0133589689810.3969/j.issn.1001-5256.2017.05.021Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatographyWANG Qunru0ZHANG Yong1MOU Dong2Department of Gastroenterology, General Hospital of Chengdu Military Region, Chengdu 610081, ChinaDepartment of Gastroenterology, General Hospital of Chengdu Military Region, Chengdu 610081, ChinaDepartment of Gastroenterology, General Hospital of Chengdu Military Region, Chengdu 610081, ChinaObjectiveTo investigate the difference in the risk of hematobilia after therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in patients with different primary diseases. MethodsA retrospective analysis was performed for the clinical data of 685 patients with pancreaticobiliary diseases who underwent therapeutic ERCP in General Hospital of Chengdu Military Region from June 2013 to June 2016. According to the presence or absence of hematobilia after ERCP, they were divided into bleeding group (29 patients) and non-bleeding group (656 patients). The association between primary disease and the risk of bleeding was evaluated. The chi-square test was used for comparison of categorical data between groups, and the independent samples t-test was used for comparison of continuous data between groups. ResultsThe overall incidence rate of hematobilia after ERCP was 4.2% (29/685), and among these patients, 21 had early bleeding and 8 had delayed bleeding. The bleeding group had a significantly higher incidence rate of hypertension than the non-bleeding group (65.5% vs 256%, χ2=22.286, P<0.001). Compared with the non-bleeding group, the bleeding group had significantly higher proportions of patients with impacted ampullar stones (17.2% vs 4.6%, χ2=9.193, P=0.002), cholangiocarcinoma (10.3% vs 2.4%, χ2=6.437, P=0.011), pancreatic cancer (10.3% vs 3.0%, χ2=4.556, P=0.033), and ampullar carcinoma (6.9% vs 1.4%, χ2=5.356, P=0.021). There were no significant differences between the two groups in the proportions of patients with common bile duct stones, acute pyogenic cholangitis, acute biliary pancreatitis, bile duct inflammatory stenosis, and bile duct stenosis after bile duct surgery (all P>0.05). ConclusionPatients with impacted ampullar stones or malignant pancreaticobiliary diseases have a high risk of hematobilia after ERCP and should be given adequate preoperative preparation, effective intraoperative hemostasis, and strengthened postoperative prevention. http://www.lcgdbzz.org/qk_content.asp?id=8199
collection DOAJ
language zho
format Article
sources DOAJ
author WANG Qunru
ZHANG Yong
MOU Dong
spellingShingle WANG Qunru
ZHANG Yong
MOU Dong
Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography
Linchuang Gandanbing Zazhi
author_facet WANG Qunru
ZHANG Yong
MOU Dong
author_sort WANG Qunru
title Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography
title_short Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography
title_full Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography
title_fullStr Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography
title_full_unstemmed Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography
title_sort association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography
publisher Editorial Department of Journal of Clinical Hepatology
series Linchuang Gandanbing Zazhi
issn 1001-5256
1001-5256
publishDate 2017-05-01
description ObjectiveTo investigate the difference in the risk of hematobilia after therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in patients with different primary diseases. MethodsA retrospective analysis was performed for the clinical data of 685 patients with pancreaticobiliary diseases who underwent therapeutic ERCP in General Hospital of Chengdu Military Region from June 2013 to June 2016. According to the presence or absence of hematobilia after ERCP, they were divided into bleeding group (29 patients) and non-bleeding group (656 patients). The association between primary disease and the risk of bleeding was evaluated. The chi-square test was used for comparison of categorical data between groups, and the independent samples t-test was used for comparison of continuous data between groups. ResultsThe overall incidence rate of hematobilia after ERCP was 4.2% (29/685), and among these patients, 21 had early bleeding and 8 had delayed bleeding. The bleeding group had a significantly higher incidence rate of hypertension than the non-bleeding group (65.5% vs 256%, χ2=22.286, P<0.001). Compared with the non-bleeding group, the bleeding group had significantly higher proportions of patients with impacted ampullar stones (17.2% vs 4.6%, χ2=9.193, P=0.002), cholangiocarcinoma (10.3% vs 2.4%, χ2=6.437, P=0.011), pancreatic cancer (10.3% vs 3.0%, χ2=4.556, P=0.033), and ampullar carcinoma (6.9% vs 1.4%, χ2=5.356, P=0.021). There were no significant differences between the two groups in the proportions of patients with common bile duct stones, acute pyogenic cholangitis, acute biliary pancreatitis, bile duct inflammatory stenosis, and bile duct stenosis after bile duct surgery (all P>0.05). ConclusionPatients with impacted ampullar stones or malignant pancreaticobiliary diseases have a high risk of hematobilia after ERCP and should be given adequate preoperative preparation, effective intraoperative hemostasis, and strengthened postoperative prevention.
url http://www.lcgdbzz.org/qk_content.asp?id=8199
work_keys_str_mv AT wangqunru associationbetweenhematobiliaandprimarydiseaseaftertherapeuticendoscopicretrogradecholangiopancreatography
AT zhangyong associationbetweenhematobiliaandprimarydiseaseaftertherapeuticendoscopicretrogradecholangiopancreatography
AT moudong associationbetweenhematobiliaandprimarydiseaseaftertherapeuticendoscopicretrogradecholangiopancreatography
_version_ 1725870760868708352